Oncology

Oncology research accounts for nearly 25% of active studies globally. Since our founding, AG Mednet has fast-deployed our solutions to support thousands of Oncology trials. Within the last four years, Judi by AG Mednet has optimized over 720 Oncology-focused studies, including over 250 Phase II and 160 Phase III trials.

‍Diversity and inclusion is essential to promote health equity, and benefits scientific discovery. Judi for Eligibility, a powerful tool for evaluating and maintaining eligibility criteria in support of time-intensive cancer treatment, enables clinical teams to promote health equity, and is used on a significant number of Oncology trials—often bundled with Judi for DSMB, which provides globally compliant data collection and transport, role-based viewing restrictions for DMC and DSMB members, and a complete audit trail—to ensure trial safety; and Judi for Site and User Qualification to streamline, qualify, and monitor remote eClinical training in real-time. Judi for Monitoring seamlessly integrates essential workflows, robust security protocols, and comprehensive de-identification practices alongside HIPAA/GDPR compliance measures, catering to the most demanding requirements set forth by global privacy regulations.

Integral for cancer research, Judi for Imaging is the industry leader for DICOM image management, secure upload, storage, and retrieval of clinical data—often paired with Judi for Adjudication, the leading platform leveraged by CROs and sponsors on Oncology trials, and best-in-class for endpoint adjudication workflow management. These solutions save enormous time and expense while maintaining trial integrity. See below to browse Judi by AG Mednet's Oncology-related case studies, articles, white papers, facts sheets, and more. AG Mednet's Judi platform is used within the entire clinical trial ecosystem—across all therapeutic areas.

‍